Numab Therapeutics Reports the First Patient Dosing in P-I Multiple Ascending Dose Study of NM26 for Moderate to Severe Atopic Dermatitis
Shots:
- The first patient has been dosed in the multiple ascending dose study of the P-Ia/Ib trial evaluating NM26 (SC) in healthy volunteers & adult patients with mod. to sev. AD. The trial is being conducted in collaboration with Asia-regional partner Kaken Pharmaceutical
- The trial focuses on evaluating the safety, tolerability, PK & immunogenicity of single & multiple ascending doses of NM26 as well as exploratory clinical activity in the MAD part of the trial. The results are expected in mid-2024
- NM26 is a bi-specific Ab that targets IL-4Rα (type I & II receptors) and IL-31 for AD. The therapy is designed to block multiple targets, targeting the underlying inflammation as well as the neuroinflammatory pathway that causes itch
Ref: Businesswire| Image: Numab Therapeutics
Related News:- Novartis Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Cosentyx (secukinumab) for Hidradenitis Suppurativa
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
